Skip to main content
Top
Published in: Obesity Surgery 11/2008

01-11-2008 | Research Article

Bariatric Therapy with Intragastric Balloon Improves Liver Dysfunction and Insulin Resistance in Obese Patients

Authors: Giorgio Ricci, Gianluca Bersani, Angelo Rossi, Flavia Pigò, Giovanni De Fabritiis, Vittorio Alvisi

Published in: Obesity Surgery | Issue 11/2008

Login to get access

Abstract

Background

Obesity is often associated with fatty liver (FL). In most cases, bright liver at ultrasound (US) and increased alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT) levels are considered the hallmarks of nonalcoholic fatty liver disease (NAFLD). Insulin resistance (IR) is the main link between obesity and NAFLD. The use of the Bioenterics® intragastric balloon (BIB) is a safe procedure either for inducing a sustained weight loss with diet support or for preparing those patients who are candidates for bariatric surgery. The aim of the study was to investigate whether the weight loss induced by intragastric balloon might improve IR and liver enzymes. The presence or absence of FL at US and the influence of a body mass index (BMI) decrease ≥10% after BIB (ΔBMI ≥ 10%) were also considered.

Methods

One hundred and three consecutive obese (BMI > 30 kg/m2) patients (38 males/65 females; mean age 41.3, range 20–63 years) underwent BIB insertion under endoscopic control. The BIB was removed 6 months later. US, clinical, and routine laboratory investigations were performed before and after BIB. IR was calculated by the homeostasis model assessment (HOMA-IR > 2.5). Exclusion criteria were hepatitis B virus positive, hepatitis C virus positive, alcohol consumption >30 g/day, history of hepato-steatogenic drugs, and type 1 diabetes.

Results

Ninety-three patients were eligible for the study. The BMI significantly decreased in all investigated patients, and it was ≥10% in 59% of the patients. FL was seen at US in 70%, impaired fasting blood glucose was present in 13%, ALT exceeded the normal limit in 30.1%, GGT exceeded the normal limit in 15%, and HOMA-IR was >2.5 in 85%. Median HOMA-IR decreased significantly in FL (4.71 vs 3.10; p < 0.05) and non-FL (3.72 vs 2.81; p < 0.01) groups. Median ALT decreased significantly in the FL group (31.5 vs 24; p < 0.001) and GGT significantly decreased in the FL group (31 vs 23.5; p < 0.05). In the FL group with ΔBMI ≥ 10%, the median values of HOMA-IR (4.95 vs 2.69; p < 0.05), ALT (30 vs 23; p < 0.01), and GGT (28 vs 20; p < 0.001) significantly decreased after BIB. In the non-FL group, HOMA-IR values significantly decreased (4.07 vs 2.36; p < 0.01) in patients with a ΔBMI ≥ 10%; ALT and GGT did not significantly decrease.

Conclusions

Weight loss induced by intragrastric balloon reduces IR. The ALT and GGT decrease suggests an improvement in hepatic damage. The benefit depends on the decrease of BMI higher than 10%.
Literature
1.
go back to reference Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRef Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRef
2.
go back to reference Bugianesi E, McCullogh AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987–1000.PubMedCrossRef Bugianesi E, McCullogh AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987–1000.PubMedCrossRef
3.
go back to reference Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753–61.PubMedCrossRef Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753–61.PubMedCrossRef
4.
go back to reference Wallace TM, Utzschneider KM, Tong J, et al. Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care. 2007;30:2673–8.PubMedCrossRef Wallace TM, Utzschneider KM, Tong J, et al. Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. Diabetes Care. 2007;30:2673–8.PubMedCrossRef
5.
go back to reference Hui JM, Hodge, A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology. 2004;40:46–54.PubMedCrossRef Hui JM, Hodge, A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology. 2004;40:46–54.PubMedCrossRef
6.
go back to reference Marchesini G, Avagnina S, Barantani EG, et al. Aminotrasferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333–9.PubMed Marchesini G, Avagnina S, Barantani EG, et al. Aminotrasferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333–9.PubMed
7.
go back to reference Burgert TS, Taksaly SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287–94.PubMedCrossRef Burgert TS, Taksaly SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287–94.PubMedCrossRef
8.
go back to reference Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotrasferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–92.PubMedCrossRef Chang Y, Ryu S, Sung E, et al. Higher concentrations of alanine aminotrasferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–92.PubMedCrossRef
9.
go back to reference Bellentani S, Delle Grave R, Suppini A, Marchesini G, and the Fatty Liver Italian Network (FLIN). Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–54.PubMedCrossRef Bellentani S, Delle Grave R, Suppini A, Marchesini G, and the Fatty Liver Italian Network (FLIN). Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–54.PubMedCrossRef
10.
go back to reference Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007;17:910–9.PubMedCrossRef Wolf AM, Beisiegel U. The effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007;17:910–9.PubMedCrossRef
11.
go back to reference Mathus-Vligen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance and efficacy of 1-year balloon treatment followed by 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.CrossRef Mathus-Vligen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance and efficacy of 1-year balloon treatment followed by 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.CrossRef
12.
go back to reference Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
13.
go back to reference Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–9.PubMedCrossRef Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–9.PubMedCrossRef
14.
go back to reference Genco A, Cipriano M, Bacci V, et al. Bioenterics® Intragastric Ballon (BIB®): a short-term double-bind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.CrossRef Genco A, Cipriano M, Bacci V, et al. Bioenterics® Intragastric Ballon (BIB®): a short-term double-bind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.CrossRef
15.
go back to reference Rossi A, Bersani G, Ricci G, Petrini C, De Fabritiis G, Alvisi V. Intrgastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg. 2007;17:1346–9.PubMedCrossRef Rossi A, Bersani G, Ricci G, Petrini C, De Fabritiis G, Alvisi V. Intrgastric balloon insertion increases the frequency of erosive esophagitis in obese patients. Obes Surg. 2007;17:1346–9.PubMedCrossRef
16.
go back to reference Hickam IJ, Johnsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminostransferase, fasting insulin, and quality of life. Gut. 2004;53:413–9.CrossRef Hickam IJ, Johnsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminostransferase, fasting insulin, and quality of life. Gut. 2004;53:413–9.CrossRef
17.
go back to reference Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101–5PubMedCrossRef Al-Momen A, El-Mogy I. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2005;15:101–5PubMedCrossRef
18.
go back to reference Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl trasferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–86.PubMedCrossRef Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl trasferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–86.PubMedCrossRef
Metadata
Title
Bariatric Therapy with Intragastric Balloon Improves Liver Dysfunction and Insulin Resistance in Obese Patients
Authors
Giorgio Ricci
Gianluca Bersani
Angelo Rossi
Flavia Pigò
Giovanni De Fabritiis
Vittorio Alvisi
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 11/2008
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-008-9487-x

Other articles of this Issue 11/2008

Obesity Surgery 11/2008 Go to the issue